Amalgamated Bank Reduces Stock Position in DaVita Inc. (NYSE:DVA)

Amalgamated Bank trimmed its holdings in DaVita Inc. (NYSE:DVA) by 42.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,032 shares of the company’s stock after selling 7,287 shares during the period. Amalgamated Bank’s holdings in DaVita were worth $1,645,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Blue Trust Inc. grew its position in shares of DaVita by 58.6% in the second quarter. Blue Trust Inc. now owns 211 shares of the company’s stock valued at $29,000 after purchasing an additional 78 shares in the last quarter. Family Firm Inc. purchased a new position in DaVita during the 2nd quarter valued at about $43,000. Versant Capital Management Inc increased its position in shares of DaVita by 90.6% during the second quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock valued at $45,000 after buying an additional 155 shares during the period. Friedenthal Financial purchased a new stake in shares of DaVita in the second quarter worth about $48,000. Finally, Point72 Hong Kong Ltd bought a new position in shares of DaVita in the second quarter valued at approximately $68,000. Institutional investors own 90.12% of the company’s stock.

DaVita Stock Performance

NYSE:DVA opened at $158.03 on Wednesday. DaVita Inc. has a 1-year low of $84.64 and a 1-year high of $168.50. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. The business has a 50 day moving average of $157.34 and a 200 day moving average of $147.23. The company has a market capitalization of $12.96 billion, a price-to-earnings ratio of 17.05, a PEG ratio of 0.84 and a beta of 0.89.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). The business had revenue of $3.26 billion during the quarter, compared to analysts’ expectations of $3.25 billion. DaVita had a net margin of 6.53% and a return on equity of 88.18%. DaVita’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same period last year, the company posted $2.85 EPS. On average, sell-side analysts predict that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

Analyst Ratings Changes

DVA has been the topic of several recent analyst reports. Barclays increased their target price on shares of DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. TD Cowen lifted their price objective on DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research note on Wednesday, July 24th. UBS Group raised their price target on DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 8th. Truist Financial boosted their price objective on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a report on Monday, October 7th. Finally, Bank of America raised their target price on shares of DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research note on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, DaVita currently has a consensus rating of “Hold” and an average target price of $161.80.

Insider Activity

In other news, CEO Javier Rodriguez sold 32,176 shares of the business’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $155.93, for a total value of $5,017,203.68. Following the completion of the sale, the chief executive officer now owns 905,659 shares of the company’s stock, valued at approximately $141,219,407.87. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, COO Michael David Staffieri sold 9,539 shares of DaVita stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $150.03, for a total value of $1,431,136.17. Following the transaction, the chief operating officer now directly owns 241,945 shares of the company’s stock, valued at $36,299,008.35. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Javier Rodriguez sold 32,176 shares of the stock in a transaction on Monday, August 26th. The shares were sold at an average price of $155.93, for a total transaction of $5,017,203.68. Following the sale, the chief executive officer now directly owns 905,659 shares of the company’s stock, valued at $141,219,407.87. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 165,625 shares of company stock valued at $26,238,297. 2.00% of the stock is currently owned by insiders.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.